Device user fee legislation
This article was originally published in The Gray Sheet
Executive Summary
Should be delayed until effectiveness of existing drug user fee legislation can be assessed, Robert Britain, vice president of the National Electrical Manufacturers Association's diagnostic imaging and therapy systems division said at an April 1 hearing of the House Appropriations agriculture subcommittee. Testifying on FDA appropriations for fiscal 1994, Britain said that the Prescription Drug User Fee Act of 1992 "should be given a chance to work before additional discussions regarding the assessment of user fees from the medical device industry are initiated".